EMA Updates Board On Business Continuity And Coronavirus
Plan Safeguards Core Agency Activities In Light Of Coronavirus Pandemic
Executive Summary
The European Medicines Agency’s first management board meeting of 2020 was held virtually and was shortened but covered a number of topics including COVID-19.
You may also be interested in...
EMA Postpones Events, Holds Virtual Meetings To Cut COVID-19 Risk
The European medicines regulator wants to restrict the number of visitors coming to its offices to reduce the risk of coronavirus infection.
The Stakes Are High So Get It Right: CHMP Oral Explanations & FDA AdComs
The stakes are extremely high for companies called before EU or US regulators and scientific experts to answer queries about their new drug applications at the later stages of the review process. How they perform is critical. Consultant Kate Dion has a raft of helpful tips for companies facing this daunting situation. Neena Brizmohun reports.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.